Amerika Serikat - Inggris - NLM (National Library of Medicine)

shiseido americas corporation - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), ensulizole (unii: 9yq9di1w42) (ensulizole - unii:9yq9di1w42) - - helps prevent sunburn - if used as directed with other sun protection measures (see directions ), decreases the risk of skin cancer and early skin aging caused by the sun

Kanada - Inggris - Health Canada

total health centre - barium chloride - liquid - 6x - barium chloride 6x - homeopathic products

Amerika Serikat - Inggris - NLM (National Library of Medicine)

allergan, inc. - estradiol acetate (unii: 5r97f5h93p) (estradiol - unii:4ti98z838e) - estradiol 0.05 mg in 1 d - femring is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active dvt, pe, or history of these conditions - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions - known anaphylactic reaction or angioedema to femring - known liver impairment or disease  - known protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders - known or suspected pregnancy  femring should not be used during pregnancy [ see   contraindications (4) ] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. femring should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. detectabl

Amerika Serikat - Inggris - NLM (National Library of Medicine)

allergan, inc. - estradiol acetate (unii: 5r97f5h93p) (estradiol - unii:4ti98z838e) - estradiol 0.05 mg in 1 d

Amerika Serikat - Inggris - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium (mg++ ) level is usually below the lower limit of normal (1.5 to 2.5 meq/liter) and the serum calcium (ca++ ) level is normal (4.3 to 5.3 meq/liter) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection, usp is also indicated for the prevention and control of seizures (convulsions) in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

cardinal health - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia.  in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in a pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

skinfood co., ltd. - titanium dioxide (unii: 15fix9v2jp) (titanium - unii:d1jt611tne), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51) - titanium dioxide 2.32 ml in 30 ml - purpose: uva/uvb protection (spf20 pa+) indication and usage: after your daily skin care regimen, apply an even layer onto the face in upward and outward motions.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

skinfood co., ltd. - titanium dioxide (unii: 15fix9v2jp) (titanium - unii:d1jt611tne), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51) - titanium dioxide 2.32 ml in 30 ml - purpose: uva/uvb protection (spf20 pa+) indication and usage: after your daily skin care regimen, apply an even layer onto the face in upward and outward motions.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

actavis pharma, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw) - levonorgestrel 52 mg - liletta®  is indicated for prevention of pregnancy for up to 6 years. liletta is contraindicated when one or more of the following conditions exist: - pregnancy [see use in specific populations (8.1)] - for use as post-coital contraception (emergency contraception) - congenital or acquired uterine anomaly, including fibroids, that distorts the uterine cavity and would be incompatible with correct ius placement [see warnings and precautions (5.10)] - acute pelvic inflammatory disease (pid) or endometritis or a history of pid unless there has been a subsequent intrauterine pregnancy [see warnings and precautions (5.4)] - infected abortion in the past 3 months [see warning and precautions (5.2.)] - known or suspected uterine or cervical neoplasia - known or suspected breast cancer or other hormone-sensitive cancer, now or in the past [see warnings and precautions (5.9)] - uterine bleeding of unknown etiology [see warnings and precautions (5.10)] - untreated acute cervicitis or vaginitis, including bacterial vagi